Case Note & Summary
The dispute arose from the patent application filed by the appellant for the beta crystalline form of Imatinib Mesylate, a drug used for treating chronic myeloid leukemia. The application was initially submitted on July 17, 1998, during a transitional phase of India's patent law, which was undergoing significant changes to comply with international agreements. The core legal questions revolved around the interpretation of section 3(d) of the Patents Act, 1970, which restricts the patentability of certain pharmaceutical products that do not demonstrate a significant inventive step. The Assistant Controller of Patents rejected the application, citing prior art and the obviousness of the claimed invention. The appellant challenged this decision in the Intellectual Property Appellate Board (IPAB), which upheld the rejection based on section 3(d) but reversed findings on anticipation and obviousness. The IPAB emphasized that the amended section 3(d) imposes a higher standard for patentability, particularly for pharmaceutical substances. The Supreme Court was approached directly under Article 136 of the Constitution, and after considering the importance of the issues at stake, it decided to hear the case on merits. The court ultimately upheld the IPAB's decision, affirming that the beta crystalline form of Imatinib Mesylate did not satisfy the requirements of section 3(d) and thus could not be granted a patent. The court highlighted the need to balance patent rights with public health considerations, particularly in the context of life-saving drugs. The decision underscored the legislative intent behind the amendments to the Patents Act, aimed at preventing evergreening and ensuring access to affordable medicines (Paras 1-20).
Headnote
A) Patent Law - Patentability Criteria - Section 3(d) of the Patents Act, 1970 - The court examined whether the beta crystalline form of Imatinib Mesylate qualifies as a patentable invention under the amended provisions of the Patents Act, particularly section 3(d), which requires a higher standard of inventive step. The court held that the appellant's product did not meet the criteria for patentability as it was deemed to not involve a significant technical advance over existing knowledge (Paras 17-19).
Issue of Consideration
Interpretation of section 3(d) of the Patents Act, 1970 and its application to the patentability of Imatinib Mesylate
Final Decision
The Supreme Court upheld the IPAB's decision, affirming that the beta crystalline form of Imatinib Mesylate did not satisfy the requirements of section 3(d) of the Patents Act, 1970, and thus could not be granted a patent.
Law Points
- Patentability
- Section 3(d) of Patents Act
- 1970
- inventive step
- public health considerations
- transitional patent regime
